Temocillin susceptibility among Enterobacterales strains recovered from blood culture in France.
Antibiotic resistance
Cephalosporinase-overproducing strain (COPE)
Extended-spectrum beta-lactamases (ESBL)
Temocillin
Third-generation cephalosporin (3GC)
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
10
11
2020
accepted:
05
03
2021
pubmed:
5
4
2021
medline:
21
9
2021
entrez:
4
4
2021
Statut:
ppublish
Résumé
Temocillin is used for several years in some European countries but, only since 2015 in France. We assessed the susceptibility of Enterobacterales strains isolated from blood culture 1 year before (2014) and 2 years after (2017) its use in France. 1,387 strains were included by 17 clinical laboratories located throughout France: 363 in 2014 and 1,024 in 2017. The rate of resistance to temocillin was 4.6% and 26.7% in 3rd generation cephalosporin (3GC) susceptible and resistant strains respectively. Cephalosporinase-overproducer (COPE) strains were significantly more resistant to temocillin (37.7%) than ESBL-producer (ESBL-PE) (23.5%) (P < 0.01). The rate of temocillin resistance was correlated to the number of inactive beta-lactams. The rate of resistance to temocillin trend to increase from 13.9% in 2014 to 23.9% in 2017 (P < 0.01). Temocillin remains highly active against Enterobacterales but the trend in resistance should be assessed over time.
Identifiants
pubmed: 33813355
pii: S0732-8893(21)00061-4
doi: 10.1016/j.diagmicrobio.2021.115368
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Penicillins
0
temocillin
03QB156W6I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115368Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Competing interest The temocillin Etest strips (bioMérieux, Lyon, France) were provided without charge by Eumedica pharmaceutical.